12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eliquis apixaban: Phase III data

The double-blind, international Phase III AMPLIFY trial in 5,395 patients with acute VTE - symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) - showed that twice-daily oral Eliquis for 6 months met the primary endpoint of non-inferiority to conventional therapy consisting of subcutaneous enoxaparin followed by warfarin in reducing the incidence of a composite of recurrent symptomatic VTE or VTE-related death (2.3% vs. 2.7%, p<0.001 for non-inferiority). On secondary endpoints, Eliquis significantly reduced the incidence of a composite of VTE, VTE-related death or major bleeding vs. conventional therapy (2.8% vs. 4.5%, p=0.001), but...

Read the full 446 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >